To evaluate Fenugreek and Bitter apple in treatment of diabetes

To evaluate the efficacy and side effects of using the combination of Trigonella foenum-graecum L and Citrullus colocynthis (L.) (Diabetic Capsule) in treatment of diabetic patients as a complementary therapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140715018490N3

Enrollment

Registered

2018-04-16

Start date

2018-04-04

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Addition to conventional anti-diabetic drugs, capsules with 40 mg Citrullus colocynthis and 350 mg Trigonella foenum-graecum are administrated 2 times per day for 3

addition to conventional anti-diabetic drugs, capsules with 350 mg corn flour are administrated 2 times per day for 3 months.

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Presence of diabetes (FBS>126 mg/dl) To have a FBS less than 250 and HgbA1c more than 6.4 Age between 30 to 65 Not to have any additional systemic diseases like; liver, renal, rheumatologic diseases or hypertension Not to consume any anti-diabetic or corticosteroid drugs 2 weeks before the study Not to drink alcohol or use opium To have a weight between 55-100 To have a BMI between 24 to 35

Exclusion criteria

Exclusion criteria: Not agree to participate in the study. To have a FBS more than 270 mg/dl Consuming corticosteroid drugs during the study Presence of any side effects

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: At the beginning of intervention, after 2 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;HgbA1C. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;Total cholesterol. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;BS2pp. Timepoint: At the beginning of intervention, after 2 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;LDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;HDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;SGOT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;SGPT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;Alp. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;TG. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.	—

Measure

Time frame

FBS. Timepoint: At the beginning of intervention, after 2 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;HgbA1C. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;Total cholesterol. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;BS2pp. Timepoint: At the beginning of intervention, after 2 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;LDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;HDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;SGOT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;SGPT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;Alp. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.;TG. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Blood sampling.

—

Secondary

Measure	Time frame
Satisfaction of patients. Timepoint: 3 months after recruitment. Method of measurement: visual analog scale.;Tolerance. Timepoint: 3 months after recruitment. Method of measurement: visual analog scale.;Temperament. Timepoint: At the beginning of the study. Method of measurement: Questionnaire.;Drug side effects. Timepoint: 3 months after recruitment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMassih Sedigh Rahimabadi

Fasa University of Medical Sciences

sedighrm@sums.ac.ir+98 71 3825 6275

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026